BeOne Medicines (SHA:688235, HKG:6160) recorded an adjusted net income of $444.5 million in the second quarter of 2026, up 76% from $252.8 million a year prior.
Adjusted earnings per American Depository Share rose to $3.84 from $2.25 previously, according to a Wednesday Hong Kong bourse filing.
Revenue stood at $1.71 billion in the three months, up 30% from $1.32 billion in the year-ago period.
The company attributed the higher profit to a rise in revenue and improved operating leverage.
The company raised the 2026 revenue guidance to between $6.6 billion and $6.8 billion.